CeriBell, Inc (CBLL)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at CeriBell, Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 6 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 17.70 $ — 54% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 51.8% above the current price.
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Next Reporting Date
- Expected Earnings per Share
- -0.45 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.40 | – | 19 | 41.10 | -67.90 | -10 | -10 |
| 2025: Q1 | -0.36 | – | 21 | 37.90 | -62.40 | -11 | -12 |
| 2025: Q2 | -0.38 | – | 21 | 42.70 | -64.40 | -8 | -8 |
| 2025: Q3 | -0.37 | – | 23 | 31.40 | -59.60 | -11 | -12 |
| 2025: Q4 | -0.36 | – | 25 | 33.70 | -54.60 | -11 | -11 |
| 2026: Q1 | -0.52 | – | 27 | 29.30 | -74.50 | -19 | -19 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
CeriBell, Inc. ist ein Medizintechnikunternehmen in den USA.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 327 |
| Headquarters | Sunnyvale, CA |
| Website | ceribell.com |
| IPO Date | 11. Oct 2024 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Xingjuan Chao Ph.D. | Co-Founder, President, CEO & Director | 1981 |
| Josef Parvizi M.D., Ph.D. | Co-Founder, Chief Medical Advisor & Director | 1969 |
| Scott Blumberg | Chief Financial Officer | – |
| Raymond Woo Ph.D. | Chief Technology Officer | 1983 |
| Dan Rogy | Senior Vice President of Operations | – |
| Louisa Daniels J.D., M.B.A. | General Counsel | 1958 |
| Brian P. Price | Senior Vice President of Marketing | – |
| Kim McKeon | VP of People & Culture | – |
| Baharan Kamousi Ph.D. | Senior Vice President of Data Science | – |
| Joseph Sean Manni | Chief Revenue Officer | 1974 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 28. Jul 2026 | West Thomas A. | Director | Other | 16,011 | 0.00 | – |
| 28. Jul 2026 | O'keefe Sharon | Director | Other | 16,011 | 0.00 | – |
| 7. Jul 2026 | Chao Xingjuan | President and CEO | Sell | 23,554 | 19.90 | 468,725 |
| 7. Jul 2026 | Chao Xingjuan | President and CEO | Other | 23,554 | 4.70 | 110,704 |
| 7. Jul 2026 | Chao Xingjuan | President and CEO | Sell | 1,446 | 19.90 | 28,775 |
| 7. Jul 2026 | Chao Xingjuan | President and CEO | Other | 1,446 | 4.70 | 6,796 |
| 7. Jul 2026 | Chao Xingjuan | President and CEO | Sell | 14,000 | 19.90 | 278,600 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.